Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Luciano J. Costa et al.|New England Journal of Medicine|2023Cited by 695
Deregulation and Targeting of TP53 Pathway in Multiple MyelomaKatarina Jovanović, Salomon Manier, Guillaume Escure et al.|Frontiers in Oncology|2019Cited by 80
Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life populationZoé Van de Wyngaert, Eileen M. Boyle, Benjamin Carpentier et al.|British Journal of Haematology|2019Cited by 29
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis‐Pistofidis, Salomon Manier|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2